The development of the world’s first lung biosimulator device to investigate orally inhaled products (OIPs) under deep lung conditions – A proof of concept project.

隆隆是将药物输送到体内治疗各种疾病的一种极好的方式。这是因为它们有很大的表面积，湿润，血液供应充足。与片剂药物不同的是，片剂药物通常在肠道中缓慢吸收，然后被肝脏处理，然后才能发挥作用，而吸入药物吸收更快，发挥作用更快。因此，吸入性药物的剂量通常比口服形式小，副作用更少，起效更快，这可以更好地控制疾病症状，改善患者的预后。当制药公司开发吸入性药物时，例如治疗哮喘，他们主要关注的是让小尺寸的药物颗粒到达肺的最深处，在那里这些颗粒被假定为被人体吸收。然而，人们对这种药物与肺液相互作用的方式知之甚少。这一点很重要，因为肺液是通过吸入途径输送的药物的初始接触点，以及药物溶解/释放的介质。显然，了解药物与肺液之间的相互作用是了解药物释放机制的关键。目前还没有可用的技术来模拟深肺的环境，从而可以研究这些类型的相互作用。Pulmorix正在开发一种复制肺条件的创新技术。这项研究的目的是建立一种方法，在一个非常类似于深肺的环境中，我们可以研究吸入药物如何与肺液相互作用。这些信息对设计吸入性药物的科学家很有价值，因为这项技术产生的信息将帮助他们开发改进的药物配方--这最终将提高患者的生活质量(例如，对于哮喘或糖尿病患者)。

Thelungs are an excellent way of delivering pharmaceutical drugs into the body to treatvarious diseases. This is because they have a large surface area, are moist and have a goodblood supply. Unlike tablet medicines, which are often slowly absorbed in the gut and thenprocessed by the liver before they can have their effect, inhaled drugs are absorbed morerapidly and exert their effects quicker. Consequently, inhaled drugs are often in smaller dosesthan oral forms, give fewer side-effects and likely to have a quicker onset of action, which canlead to better control of disease symptoms and improved patient outcomes.When pharmaceutical companies are developing inhaled drugs, for example for asthma, theyare mainly concerned with getting small-sized drug particles to reach the deepest parts of thelung where it is assumed that the particles are absorbed into the body. However, little isknown about the way the drug interacts with the lung fluids. This is important to know as thelung fluids are the initial point of contact for the drugs delivered by the inhaled route and themedia in which the drug dissolves/is released. Clearly, it is crucial to understand theinteraction between pharmaceutical drugs and the lung fluids so that drug release mechanismscan be understood. There is currently no technology available to simulate the environment ofthe deep lung so that these types of interactions can be researched.Pulmorphix is in the process of developing an innovative technology which replicates lungconditions. The objective of this research is to set up ways in which we can investigate howinhaled drugs interact with lung fluids in an environment which closely resembles that of thedeep lung. This information is of value to scientists designing inhaled drugs as theinformation generated by this technology will help them develop improved drug formulations -which will ultimately improve patient quality of life (e.g. for individuals with asthma ordiabetes).